Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.47 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5321053 | 0.90 | HSD17B10 (0.65) | ALDH1A1LMNAMAPTTP53PKM | |
| SCHEMBL6771522 | 0.87 | ALDH1A1 (0.59) | ALDH1A1MAPTCDK1PKMTDP1 | |
| SCHEMBL2318661 | 0.85 | ALDH1A1 (1.00) | ALDH1A1LMNAMAPTTP53CDK1 | |
| SCHEMBL14502114 | 0.85 | ALDH1A1 (0.76) | ALDH1A1LMNAMAPTTP53CDK1 | |
| Hydrochloric Acid SCHEMBL7531560 | 0.83 | ALDH1A1 (0.73) | ALDH1A1LMNAMAPTTP53CDK1 | |
| SCHEMBL6192129 | 0.83 | ALDH1A1 (0.73) | ALDH1A1LMNAMAPTTP53CDK1 | |
| SCHEMBL24809088 | 0.82 | ALDH1A1 (0.71) | ALDH1A1LMNAMAPTTP53CDK1 | |
| SCHEMBL686781 | 0.82 | ALDH1A1 (0.54) | ALDH1A1LMNAMAPTCDK1ATAD2 | |
| SCHEMBL6770516 | 0.82 | ALDH1A1 (0.54) | ALDH1A1LMNAMAPTCDK1ATAD2 | |
| SCHEMBL2314592 | 0.81 | ALDH1A1 (0.69) | ALDH1A1LMNAMAPTTP53CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024928-A1 | 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES | BioVersys AG (CH) | 2022-01-27 | — | — | US | disclosed |
| WO-2020109350-A1 | 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES | BioVersys AG (CH) | 2020-06-04 | — | — | WO | disclosed |
| EP-2758399-B1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2017-11-15 | — | — | EP | disclosed |
| EP-2341140-B1 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION AS (DK) | 2017-07-19 | — | — | EP | disclosed |
| US-20160175304-A1 | N-[4-(1H-PYRAZOLO[3,4-b]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2016-06-23 | — | — | US | disclosed |
| US-9221828-B2 | N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl]sulfonamides as pharmaceuticals | SANOFI (FR) | 2015-12-29 | — | — | US | disclosed |
| US-9174993-B2 | N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals | SANOFI (FR) | 2015-11-03 | — | — | US | disclosed |
| US-9175003-B2 | Substituted azoanthracene derivatives and intermediates for preparation thereof | VTV THERAPEUTICS LLC (US) | 2015-11-03 | — | — | US | disclosed |
| EP-2413693-B1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC (US) | 2015-09-09 | — | — | EP | disclosed |
| EP-2570415-B1 | N-[4-(1H-Pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals | SANOFI SA (FR) | 2015-08-26 | — | — | EP | disclosed |
| EP-1954133-A2 | PYRROLIDINEANILINES | SMITHKLINE BEECHAM CORPORATION (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1858890-A1 | NOVEL ANTITHROMBOTIC SUBSTITUTED PYRROLIDINONES, THE PRODUCTION AND USE THEREOF IN THE FORM OF MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2007-11-28 | — | — | EP | disclosed |
| WO-2007065093-A2 | PYRROLIDINEANILINES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20060217435-A1 | New Substituted Pyrrolidinones and Their Use as Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-09-28 | — | — | US | disclosed |
| WO-2006089909-A1 | NOVEL ANTITHROMBOTIC SUBSTITUTED PYRROLIDINONES, THE PRODUCTION AND USE THEREOF IN THE FORM OF MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-31 | — | — | WO | disclosed |
| EP-1360170-A1 | CARBOXYLIC AMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-11-12 | — | — | EP | disclosed |
| EP-1360166-A1 | SUPPORT FOR USE IN CATALYST FOR PRODUCING LOWER ALIPHATIC CARBOXYLIC ACID ESTER, CATALYST FOR PRODUCING LOWER ALIPHATIC CARBOXYLIC ACID ESTER USING THE SUPPORT, PROCESS FOR PRODUCING THE CATALYST, AND PROCESS FOR PRODUCING LOWER ALIPHATIC CARBOXYLIC ACID ESTER USING THE CATALYST | Showa Denko K.K. (JP) | 2003-11-12 | — | — | EP | disclosed |
| US-20020151595-A1 | Carboxylic acid amides having antithrombotic activity | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | disclosed |
| WO-2002064541-A1 | SUPPORT FOR USE IN CATALYST FOR PRODUCING LOWER ALIPHATIC CARBOXYLIC ACID ESTER, CATALYST FOR PRODUCING LOWER ALIPHATIC CARBOXYLIC ACID ESTER USING THE SUPPORT, PROCESS FOR PRODUCING THE CATALYST, AND PROCESS FOR PRODUCING LOWER ALIPHATIC CARBOXYLIC ACID ESTER USING THE CATALYST | SHOWA DENKO K. K. (JP) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002062748-A1 | CARBOXYLIC AMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217435-A1 | New Substituted Pyrrolidinones and Their Use as Medicaments | PYCR1, S100A9, REV1 | ALDH1A1 1594/4885LMNA 1767/4885MAPT 632/4885 |
| US-20220024928-A1 | 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES | OR10J3, ORC3, CBR3 | ALDH1A1 1547/4885LMNA 3949/4885MAPT 4658/4885 |
| US-20160175304-A1 | N-[4-(1H-PYRAZOLO[3,4-b]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SGK1, SGK3, SGK2 | ALDH1A1 2371/4885LMNA 3124/4885MAPT 3688/4885 |
| US-20020151595-A1 | Carboxylic acid amides having antithrombotic activity | SERPINC1, TFPI, F2 | ALDH1A1 112/4885LMNA 1147/4885MAPT 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.